Deciphera Pharmaceuticals (DCPH) Tops Q1 EPS by 10c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Deciphera Pharmaceuticals (DCPH) Tops Q1 EPS by 10c

Deciphera Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results

May 4, 2022 7:00 AM EDT

First Quarter 2022 Revenue of $29.2 Million

Net Proceeds of $163.4 Million from Public Offering in April, Enabling the Company to Fund Operating and Capital Expenditures into 2025

Pivotal Phase 3 MOTION Study of Vimseltinib in TGCT Patients Underway; Updated Phase 1/2 Results Expected in 2H 2022

Preclinical Data for DCC-3116 in Combination with KRASG12C Inhibitors Presented at the AACR Annual Meeting Demonstrating Deeper and Longer Tumor Regressions in Mutant KRASG12C NSCLC Models In Vivo

Phase 1 Single Agent Dose Escalation Data for DCC-3116 Expected in 2H 2022

New... More